Stoke therapeutics stock.

28 Sept 2023 ... STOKE THERAPEUTICS, INC. 45 Wiggins Avenue. Bedford, MA 01730. NOTICE OF SPECIAL MEETING OF STOCKHOLDERS. To Be Held October 24, 2023. To Our ...

Stoke therapeutics stock. Things To Know About Stoke therapeutics stock.

About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is …Mar 16, 2023 · Stoke Therapeutics (STOK) In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Stoke Therapeutics, with a price target of $25.00. The company’s shares closed last ... According to the issued ratings of 8 analysts in the last year, the consensus rating for Stoke Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 6 buy ratings for STOK. The average twelve-month price prediction for Stoke Therapeutics is $21.00 with a high price target of $35.00 and a low price target of $12.00.Nov 14, 2022 · Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program. ... Stoke had approximately $252.2 million in cash, cash equivalents, marketable securities, and ...

BEDFORD - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 - 5, in Orlando, Florida.Jan 10, 2022 · About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense ...

Stoke Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.67. See the top stocks recommended by analysts >> The company has a one-year high of $26.60 and a ...scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023. Find the latest scPharmaceuticals Inc. (SCPH) stock quote, history, news and other vital ...

Stoke Therapeutics (NASDAQ:STOK), a leading biotechnology company, has experienced significant fluctuations in its stock price over the past year. As of July 28, 2023, shares of STOK stock opened at a modest $6.14 on Friday, far from its 12-month high of $22.87.Find the latest Cognition Therapeutics, Inc. (CGTX) stock quote, history, news and other vital information to help you with your stock trading and investing.On Friday 11/17/2023 the closing price of the Stoke Therapeutics Inc Registered Shs share was $4.22 on NAS. Compared to the opening price on Friday 11/17/2023 on NAS …Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 10.35% so far this month. During the month of July, Stoke Therapeutics Inc’s stock price has reached a high of $12.45 and a low of $9.49. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ...

Stoke Media & Investor Contacts: Dawn Kalmar Chief Communications Officer [email protected] 781-303-8302 Eric Rojas Vice President, Investor Relations [email protected] 617-312-2754 Source: Stoke Therapeutics, Inc.

Stoke Therapeutics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Stoke Therapeutics, Inc. (Nasdaq: …

Beam Therapeutics ( BEAM 0.68%) recently signed a major research deal with Pfizer ( PFE 0.59%) that could be worth up to $1.35 billion, and hardly anyone seemed to notice. This was clearly great ...Stoke Therapeutics (STOK) (Delayed Data from NSDQ) $3.79 USD -0.06 (-1.56%) Updated Nov 30, 2023 04:00 PM ET After-Market: $3.77 -0.02 (-0.53%) 5:10 PM …Dec 1, 2023 · STOK Earnings Date and Information. Stoke Therapeutics last posted its quarterly earnings data on November 7th, 2023. The reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.10. The business earned $3.31 million during the quarter, compared to analyst estimates of $3.83 million. See the latest Stoke Therapeutics Inc stock price (STOK:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – 5, in Orlando, Florida.Stoke Therapeutics Inc (STOK) has been gaining attention from investors and analysts due to its potential for growth. On November 7, 2023, the stock was trading at a price of $4.52. However, analysts have a median target price of $20.00 for the stock, with a high estimate of $35.00 and a low estimate of $13.00.PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 1, 2023, the company approved non-statutory stock options to purchase an aggregate of 14,005 shares of its common stock and ...

Epilepsy & Behavior. November 1, 2022. READ FULL ARTICLE ; Science Translational Medicine. August 26, 2020. Read Full Article ; Nature Communications. July 9, ...34.02%. Get the latest Stoke Therapeutics Inc (STOK) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 10.35% so far this month. During the month of July, Stoke Therapeutics Inc’s stock price has reached a high of $12.45 and a low of $9.49. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ...Son STK-002 est un ASO en développement préclinique pour le traitement de l'atrophie optique autosomique dominante (ADOA). Le STK-002 est conçu pour augmenter l ...Find the latest Gain Therapeutics, Inc. (GANX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find the latest Monopar Therapeutics Inc. (MNPR) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently up 8.66% so far this month. During the month of June, Stoke Therapeutics Inc’s stock price has reached a high of $12.20 and a low of $10.69. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ...

The company said it has returned $4.2 billion in common stock dividends and buybacks from the start of 2022 through the third quarter of 2023, while generating …Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 10.35% so far this month. During the month of July, Stoke Therapeutics Inc’s stock price has reached a high of $12.45 and a low of $9.49. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ...Find the latest Intellia Therapeutics, Inc. (NTLA) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.67. See the top stocks recommended by analysts >> The company has a one-year high of $26.60 and a ...Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – 5, in Orlando, Florida.Nov 7, 2023 · Stoke Therapeutics Inc (STOK) has been gaining attention from investors and analysts due to its potential for growth. On November 7, 2023, the stock was trading at a price of $4.52. However, analysts have a median target price of $20.00 for the stock, with a high estimate of $35.00 and a low estimate of $13.00. Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program. ... Stoke had approximately $252.2 million in cash, cash equivalents, marketable securities, and ...Stoke Therapeutics (NASDAQ:STOK), a leading biotechnology company, has experienced significant fluctuations in its stock price over the past year. As of July 28, 2023, shares of STOK stock opened at a modest …Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.63 per share a year ago.

Director. Our story began in the lab with our founders, who shared a passion to address genetic diseases. Cookie. Duration. Description. cookielawinfo-checkbox-advertisement. 1 year. Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category . cookielawinfo-checkbox ...

Stoke Therapeutics Stock Price Chart Technical Analysis: Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and STOK is experiencing slight selling pressure.

Stoke Therapeutics (STOK) In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Stoke Therapeutics, with a price target of $25.00. The company’s shares closed last ...Stoke Therapeutics Stock Performance Shares of STOK stock opened at $3.95 on Friday. Stoke Therapeutics, Inc. has a 52-week low of $3.35 and a 52-week …Nov 17, 2023 · Stoke Therapeutics Inc (NASDAQ: STOK) has seen a decline in its stock price by -9.54 in relation to its previous close of 4.61. However, the company has experienced a -7.95% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2023-09-10 that Stoke Therapeutics (STOK) stock is down 40% after failing to meet ... Heron Therapeutics, Inc. (NASDAQ:HRTX) posted its quarterly earnings data on Thursday, March, 23rd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.08. The biotechnology company had revenue of $30 million for the quarter, compared to the …Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business. Find the latest Altamira Therapeutics Ltd. (CYTO) stock quote, history, news and other vital information to help you with ...The Stoke Therapeutics stock forecast for tomorrow is $ 4.11, which would represent a -2.63% loss compared to the current price. In the next week, the price of STOK is expected to increase by 2.93% and hit $ 4.34.. As far as the long-term Stoke Therapeutics stock forecast is concerned, here’s what our predictions are currently suggesting.Ms. Burstein STOK stock SEC Form 4 insiders trading. Jennifer has made over 17 trades of the Stoke Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 2,500 units of STOK stock worth $28,375 on 10 December 2018.. The largest trade she's ever made was exercising 2,500 units of Stoke …Stoke Therapeutics, Inc. (STOK) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. As of 03:57PM EST. Market open. View the basic STOK option chain and compare options of Stoke Therapeutics ...Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eight research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The […]BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 6, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates.Find the latest Inovio Pharmaceuticals, Inc. (INO) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – …

Stoke Therapeutics Inc (STOK) has experienced a 27.30% rise in stock performance for the past week, with a 28.31% rise in the past month, and a -13.08% drop in the past quarter. The volatility ratio for the week is 8.16%, and the volatility levels for the past 30 days are at 6.66% for STOK. The simple moving average for the past 20 days is 25. ...Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 10.35% so far this month. During the month of July, Stoke Therapeutics Inc’s stock price has reached a high of $12.45 and a low of $9.49. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ...4 equities research analysts have issued 1-year target prices for Viracta Therapeutics' shares. Their VIRX share price targets range from $5.00 to $16.00. On average, they predict the company's share price to reach $9.25 in the next twelve months. This suggests a possible upside of 1,645.3% from the stock's current price.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Instagram:https://instagram. used f 150 lightninginvertir en tesla hoyhome builder stocksvsp plans for seniors Stoke Therapeutics (STOK) In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Stoke Therapeutics, with a price target of $35.00.The company’s shares closed ...Dec 31, 2022 · BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 6, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates. nso malpractice insurance reviewscybin stock forecast 2023 Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.Stock Quote. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low. liberty global inc In therapeutic settings, understanding the dynamics and relationships within a family system is crucial for effective treatment. One tool that has proven to be invaluable in this process is the family genogram.Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2023 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide (ASO) which is in ...Ms. Burstein STOK stock SEC Form 4 insiders trading. Jennifer has made over 17 trades of the Stoke Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 2,500 units of STOK stock worth $28,375 on 10 December 2018.. The largest trade she's ever made was exercising 2,500 units of Stoke …